ReviewOncotarget2017
The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The diagnostic value of circulating microRNAs as a biomarker for gastric cancer: A meta‑analysis.Oncology reports · 2019Pooled it
- Trial
- Nano-biosensors for circulating tumor markers: advancing liquid biopsy toward precision cancer diagnostics.Journal of cancer research and clinical oncology · 2026Review
- Investigating the expression of CTLA-4 and CD28 genes as immune regulators in patients with colorectal polyps.BMC cancer · 2026Article
- miR-17: from developmental regulatory hub to molecular engine driving tumourigenesis.Frontiers in oncology · 2026Review
- The role of microRNAs in gastritis, intestinal metaplasia, and gastric cancer: a narrative review.Translational cancer research · 2025Review
- Identification of miR-20a as a Diagnostic and Prognostic Biomarker in Colorectal Cancer: MicroRNA Sequencing and Machine Learning Analysis.MicroRNA (Shariqah, United Arab Emirates) · 2025Article
- Crosstalk between bile acids and gut microbiota: a potential target for precancerous lesions of gastric cancer.Frontiers in pharmacology · 2025Review
- Gastric Intestinal Metaplasia: Challenges and the Opportunity for Precision Prevention.Cancers · 2023Review
- Cancer Stem Cells in Tumor Microenvironment of Adenocarcinoma of the Stomach, Colon, and Rectum.Cancers · 2022Review
- MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy.International journal of molecular sciences · 2022Article
- Downregulated miR-18a and miR-92a synergistically suppress non-small cell lung cancer via targetingBioengineered · 2022Article
- Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy.Journal of hematology & oncology · 2022Review
- Article
- Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions.International journal of molecular sciences · 2021Review
- Molecular Alterations in Gastric Intestinal Metaplasia.International journal of molecular sciences · 2021Review
- Expression Profile of miRNA-17-3p and miRNA-17-5p Genes in Gastric Cancer Patients with Helicobacter pylori Infection.Journal of gastrointestinal cancer · 2021Observational
- Expression and clinical significance of miR-338 and miR-20a in serum of patients with gastric carcinoma.American journal of translational research · 2021Article
- MiR-484 suppressed proliferation, migration, invasion and induced apoptosis of gastric cancer via targeting CCL-18.International journal of experimental pathology · 2020Article
- The MiR-17-92 Gene Cluster is a Blood-Based Marker for Cancer Detection in Non-Small-Cell Lung Cancer.The American journal of the medical sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntestinal metaplasia is considered to be a pre-cancerous lesion of gastric cancer. The miR-17-92 cluster was previously reported to have clinical value in the prediction of cancer development. This study aimed to test the diagnostic value of miR-17-92 in gastric cancer and the intestinal metaplasia patients compared with the normal ones.
resultsThe results showed that miR-17-92 members were over-expressed in the serum of both gastric cancer and intestinal metaplasia patients, compared with healthy controls. Serum miR-17-92 members could also distinguish patients with gastric cancer and intestinal metaplasia from healthy controls. MATERIALS AND
methodsSerum miR-17-92 expression levels were detected using quantitative real-time PCR in 75 patients with gastric cancer, 104 patients with intestinal metaplasia and 38 healthy controls. The Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were then analyzed to test the efficacy of the miR-17-92 members in distinguishing gastric cancer, intestinal metaplasia and healthy controls.
conclusionsIn conclusion, the miR-17-92 cluster might be useful as a potential serum biomarker for the early detection of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.